This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Quidel (QDEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neptune Wellness (NEPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neptune Wellness (NEPT) delivered earnings and revenue surprises of -50% and 7.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed at $95.02 in the latest trading session, marking a -1.43% move from the prior day.
Here's Why You Should Add Quidel (QDEL) Stock To Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.
Quidel (QDEL) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Quidel (QDEL) closed at $103.36, marking a +1.59% move from the previous day.
4 Stocks With High Net Income Ratio to Scoop Up
by Nitish Marwah
FLGT, AAWW, BBW, and QDEL passed the screen for the stocks with a high net income ratio.
Quidel (QDEL) Stock Jumps 11.2%: Will It Continue to Soar?
by Zacks Equity Research
Quidel (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.
Philips' (PHG) Q4 Earnings Hit By Supply-Chain Issues, Recall
by Zacks Equity Research
Philips (PHG) fourth-quarter and 2021 results suffer from supply-chain constraints and adverse impact of the Respironics recall.
Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed the most recent trading day at $127.71, moving -1.98% from the previous trading session.
Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
by Debanjana Dey
Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
Quidel (QDEL) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed the most recent trading day at $126.80, moving +0.51% from the previous trading session.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.
by Zacks Equity Research
Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.
3 Diagnostics Stocks in Focus Amid the Omicron Outbreak
by Riya Anand
Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.
Quidel's (QDEL) Antigen Tests Successful in Omicron Detection
by Zacks Equity Research
The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.
Company News for Dec 27, 2021
by Zacks Equity Research
Companies in the News Are: OCDX,QDEL,JD,TCEHY,TSLA,NKLA
Quidel (QDEL) Inks Buyout Deal to Solidify Its Diagnostics Arm
by Zacks Equity Research
Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.
3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022
by Debanjana Dey
Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.
Philips (PHG) to Buy Vesper Medical, Expand Vascular Portfolio
by Zacks Equity Research
Philips (PHG) is set to acquire Vesper Medical to strengthen its vascular devices portfolio and customer base.
Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.
Quidel (QDEL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 516.09% and 0.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Quidel (QDEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD's (BDX) New Manufacturing Facility to Boost Supply Readiness
by Zacks Equity Research
BD's (BDX) latest manufacturing line is expected to not only boost supply capacity but also provide priority access to needles and syringes to the U.S. government.
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
by Zacks Equity Research
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.